These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 15504943

  • 1. Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure.
    Neumann J, Ligtenberg G, Oey L, Koomans HA, Blankestijn PJ.
    J Am Soc Nephrol; 2004 Nov; 15(11):2902-7. PubMed ID: 15504943
    [Abstract] [Full Text] [Related]

  • 2. Sympathetic hyperactivity and clinical outcome in chronic kidney disease patients during standard treatment.
    Penne EL, Neumann J, Klein IH, Oey PL, Bots ML, Blankestijn PJ.
    J Nephrol; 2009 Nov; 22(2):208-15. PubMed ID: 19384838
    [Abstract] [Full Text] [Related]

  • 3. Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure.
    Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ.
    J Am Soc Nephrol; 2003 Feb; 14(2):425-30. PubMed ID: 12538743
    [Abstract] [Full Text] [Related]

  • 4. Effects of moxonidine on sympathetic nerve activity in patients with end-stage renal disease.
    Hausberg M, Tokmak F, Pavenstädt H, Krämer BK, Rump LC.
    J Hypertens; 2010 Sep; 28(9):1920-7. PubMed ID: 20634720
    [Abstract] [Full Text] [Related]

  • 5. The angiotensin receptor blocker eprosartan mesylate reduces pulse pressure in isolated systolic hypertension.
    Teitelbaum I, Chilvers M, Reiz RJ.
    Can J Cardiol; 2004 Oct; 20 Suppl C():11C-16C. PubMed ID: 16807618
    [Abstract] [Full Text] [Related]

  • 6. The effect of treatment with eprosartan on pulse pressure: factors predicting response.
    de la Sierra A, Muñoz A, Arcos E, López JS, Relats J, ETAPA-2 study investigators.
    Can J Cardiol; 2004 Oct; 20 Suppl C():17C-22C. PubMed ID: 16807619
    [Abstract] [Full Text] [Related]

  • 7. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure.
    Ligtenberg G, Blankestijn PJ, Oey PL, Klein IH, Dijkhorst-Oei LT, Boomsma F, Wieneke GH, van Huffelen AC, Koomans HA.
    N Engl J Med; 1999 Apr 29; 340(17):1321-8. PubMed ID: 10219067
    [Abstract] [Full Text] [Related]

  • 8. Impaired neuronal and vascular responses to angiotensin II in a rabbit congestive heart failure model.
    Nap A, Belterman CN, Mathy MJ, Balt JC, Pfaffendorf M, van Zwieten PA.
    J Renin Angiotensin Aldosterone Syst; 2003 Dec 29; 4(4):220-7. PubMed ID: 14689369
    [Abstract] [Full Text] [Related]

  • 9. Eprosartan effect on fibrinolytic/hemostatic variables in arterial hypertension: a comparative study to losartan.
    Makris TK, Stavroulakis G, Papadopoulos DP, Krespi P, Hatzizacharias A, Zilidis A, Tsoukala C, Votteas VE.
    Drugs Exp Clin Res; 2004 Dec 29; 30(3):125-32. PubMed ID: 15366789
    [Abstract] [Full Text] [Related]

  • 10. Tonic chemoreflex activation contributes to the elevated muscle sympathetic nerve activity in patients with chronic renal failure.
    Hering D, Zdrojewski Z, Król E, Kara T, Kucharska W, Somers VK, Rutkowski B, Narkiewicz K.
    J Hypertens; 2007 Jan 29; 25(1):157-61. PubMed ID: 17143187
    [Abstract] [Full Text] [Related]

  • 11. Sympathetic hyperactivity in hypertensive chronic kidney disease patients is reduced during standard treatment.
    Neumann J, Ligtenberg G, Klein IH, Boer P, Oey PL, Koomans HA, Blankestijn PJ.
    Hypertension; 2007 Mar 29; 49(3):506-10. PubMed ID: 17224471
    [Abstract] [Full Text] [Related]

  • 12. Angiotensin blockade with eprosartan: vascular and functional implications.
    Ram CV.
    Curr Med Res Opin; 2007 Nov 29; 23 Suppl 5():S5-11. PubMed ID: 18093408
    [Abstract] [Full Text] [Related]

  • 13. Eprosartan mesylate effectively reduces systolic and diastolic blood pressure in a Canadian primary care setting.
    Conter HS, McKay DW, Reiz RJ.
    Can J Cardiol; 2004 Oct 29; 20 Suppl C():6C-10C. PubMed ID: 16807617
    [Abstract] [Full Text] [Related]

  • 14. Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction.
    de la Sierra A, Ram CV.
    Curr Med Res Opin; 2007 Nov 29; 23 Suppl 5():S1-3. PubMed ID: 18093407
    [Abstract] [Full Text] [Related]

  • 15. Atorvastatin reduces sympathetic activity in patients with chronic kidney disease.
    Siddiqi L, Joles JA, Oey PL, Blankestijn PJ.
    J Hypertens; 2011 Nov 29; 29(11):2176-80. PubMed ID: 21897294
    [Abstract] [Full Text] [Related]

  • 16. Does blockade of the renin angiotensin system affect sympathetic and blood pressure responses to amlodipine in young hypertensive patients?
    Ruzicka M, Coletta E, Leenen FH.
    Am J Hypertens; 2007 Nov 29; 20(11):1202-8. PubMed ID: 17954368
    [Abstract] [Full Text] [Related]

  • 17. The effect of eprosartan on reflex sympathetic activation in sodium restricted patients with essential hypertension.
    Vase H, Lauridsen TG, Graffe CC, Pedersen EB.
    J Am Soc Hypertens; 2011 Nov 29; 5(5):385-94. PubMed ID: 21640689
    [Abstract] [Full Text] [Related]

  • 18. Effect of losartan on muscle sympathetic activity and baroreceptor function in systemic hypertension.
    Béchir M, Enseleit F, Chenevard R, Lüscher TF, Noll G.
    Am J Cardiol; 2005 Jan 01; 95(1):129-31. PubMed ID: 15619411
    [Abstract] [Full Text] [Related]

  • 19. Unique dual mechanism of action of eprosartan: effects on systolic blood pressure, pulse pressure, risk of stroke and cognitive decline.
    Ram CV, Rudmann MA.
    Expert Rev Cardiovasc Ther; 2007 Nov 01; 5(6):1003-11. PubMed ID: 18035916
    [Abstract] [Full Text] [Related]

  • 20. Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity.
    Dhakam Z, McEniery CM, Yasmin, Cockcroft JR, Brown MJ, Wilkinson IB.
    Am J Hypertens; 2006 Feb 01; 19(2):214-9. PubMed ID: 16448896
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.